# TaiMed Biologics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/taimed-biologics

- Industry: Biotechnology
- Headquarters: Taipei, Taiwan - China
- Website: www.taimedbiologics.com
- Total disclosed funding: $22M
- Latest round: Series B (Mar 1, 2010)
- Investors on record: 1

## About

Established in 2007 and based in Taipei, China, TaiMed Biologics Inc. operates as a biologics developer that focuses on the clinical development of biotherapeutics. It has an approximately 60,000 square feet of facility. The company is headquartered in Taipei, and has a branch in Hsinchu and a subsidiary in the USA. In March 2010, it raised USD 22 million in Series B financing from YFY Biotech Management Company. In March 2018, its product TMB-355 was approved by the US FDA as a new protein drug. Dayi He, the co-founder of the company, is an academician of Academia Sinica and director and CEO of the AIDS Research Center. The company cooperates with tanvex, WuXi AppTec and Samsung Biologics, etc.

The company is engages in the research and development of biotherapeutics. Its products include Trogarzo® intravenous injection, Trogarzo® intravenous bolus injection, Trogarzo® intramuscular injection, TMB-365 and TMB-380 double antibody compound combination. The company also provides biological agents commissioned development and manufacturing (CDMO) services.

## Funding rounds

- Series B, Mar 1, 2010, $22M — YFY Biotech Management

## Investors

- YFY Biotech Management (https://capitalatlas.ai/funds/yfy-biotech-management) — Series B